Navigation Links
Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes
Date:7/21/2011

CARLSBAD, Calif., July 21, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B.  ISIS-PTP1BRx is designed to increase the body's sensitivity to the natural hormone insulin, resulting in better glucose control for patients with type 2 diabetes.  Because of its unique mechanism ISIS-PTP1BRx has the potential to contribute to the treatment of type 2 diabetes without causing weight gain or hypoglycemia.  The reductions in LDL-C produced by PTP-1B inhibition should also provide an added benefit to patients.

"We are developing ISIS-PTP1BRx for patients whose glucose is inadequately controlled by insulin or oral therapies.  Having demonstrated the attractive profile of a PTP-1B inhibitor with ISIS 113715, we are now proceeding with the development of a more potent PTP-1B inhibitor," said Sanjay Bhanot, M.D., Ph.D., Vice President of Metabolic Disorders and Translational Medicine at Isis.  "We believe that ISIS-PTP1BRx could be a safer insulin sensitizer.  The only class of insulin sensitizers currently available also broadly affects the transcription of multiple genes, which leads to side effects.  Some of these side effects, such as increases in LDL-C, weight gain, and thinning of bones are particularly problematic in diabetics.  Because ISIS-PTP1BRx selectively reduces only the PTP-1B protein, a mechanism distinct from current insulin sensitizers, it is unlikely to have those side effects."

Earlier Phase 2 studies of ISIS 113715 provided evidence of the therapeutic potential of inhibiting PTP-1B.  In those studies, PTP-1B inhibition improved glucose control and reduced LDL-C in both newly diagnosed diabetic patients and in patients who
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
6. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. Prolexys Pharmaceuticals Initiates Phase 1 Study
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ZIONA, Israel , June 29, ... BVXV, TASE: BVXV) today announced positive preliminary results from ... candidate for a universal influenza vaccine. In this trial, ... of 50 to 65, followed by an administration of ... later. M-001 was found to be safe and well ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
(Date:6/29/2015)... Calif. , June 29, 2015  Arbor ... medical workstation lineup. The high-powered, multi-functional M2150 ... generation Intel® Haswell Core i5-4402E 1.6 ... provide significant data processing and computing performance. Integrated ... making the unit well suited for graphics-intense applications ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... , CHEYENNE, Wyo., Aug. 24 The ... of its Pay-for-Participation (P4P) program, a component of its innovative ... collaboration between the practitioner community and the Wyoming EqualityCare (EC) ... Wyoming Medicaid members. , , (Logo: ...
... Curemark Founder and CEO Dr. Joan Fallon delivered the ... Conference at Harvard Medical School on July 14th. , ... conclave is particularly significant, since epigenetics is the study of ... in the DNA sequence. Presenters at the session showcased many ...
Cached Medicine Technology:Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3Curemark CEO Presents at Epigenomics Conference 2
(Date:6/29/2015)... ... June 29, 2015 , ... World Patent Marketing, a vertically ... baby invention that makes parenthood less tiring without sacrificing your child's well being. ... of USD 52.2 billion in 2017," says Scott Cooper, CEO and Creative Director ...
(Date:6/29/2015)... ... June 29, 2015 , ... People across the country give their coworkers and families ... of our culture. , But, how often do coworkers donate “life” to the husband ... simple one. , “Dawna (Wright-Thompson) told me her husband was on a donor ...
(Date:6/29/2015)... ... June 29, 2015 , ... With Urgent Care Medicine now serving ... the American Board of Urgent Care Medicine and the Medical Society of Delaware to ... Urgent Care physicians and health care professionals. , According to Matthew Bader, Exam Master ...
(Date:6/29/2015)... San Fernando Valley, CA (PRWEB) , ... June 29, 2015 , ... ... offering non-invasive treatments designed to lift and tighten sagging skin. Ulthera is a special ... or surgery. Instead, it uses ultrasound technology to gently stimulate collagen production. Ulthera is ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... (NENA) Annual Conference shows that fewer than 10 percent of U.S. state and ... of organizations have set an implementation deadline for NG9-1-1. , “Mobile phones ...
Breaking Medicine News(10 mins):Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 4
... Feb. 17 CryoLife, Inc. (NYSE: CRY ... today,that the U.S. Food and Drug Administration (FDA) has ... heart valve. The new labeling claim,relates to reducing ... the,CryoValve SG. , CryoValve SG ...
... Will ensure at least 99.99 percent uptime ... 17 Stratus Technologies, Inc. announced that ... interactive patient communication systems, has adopted the ... as a technology foundation for its flagship ...
... Event Marks 20th Anniversary of the HBA,s Prestigious Industry ... Businesswomen,s Association (HBA) today announced that its 2009 "Woman ... Chief Executive Officer of Millennium: The Takeda Oncology Company."I ... and medicine to transform cancer from a dreaded killer ...
... decisions, study says , , MONDAY, Feb. 16 (HealthDay News) -- ... they prescribe cancer medications for uses beyond what the drugs ... According to the report, published in the Feb. 17 ... online and hard-copy resource used by oncologists and pharmacists, known ...
... Feb. 17 RediClinic announced today that it has,received ... (CCA) Quality and Safety Standards by the Jefferson School ... Board of Directors adopted 10 Quality and Safety Standards ... and accrediting,organizations, as well as its Clinical Advisory Board. ...
... Perry,s Donation to Fund Renovation of Crisis ShelterATLANTA, ... Covenant House Georgia announced today that writer/director/producer Tyler ... 15-passenger van to the Atlanta-based homeless shelter. ... the complete renovation of its Crisis Shelter for ...
Cached Medicine News:Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 2Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 3Health News:Stratus Technologies Signs Allen Technologies as Newest Channel Partner for High Availability Avance Software 2Health News:Stratus Technologies Signs Allen Technologies as Newest Channel Partner for High Availability Avance Software 3Health News:Healthcare Businesswomen's Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company 2Health News:Healthcare Businesswomen's Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company 3Health News:Healthcare Businesswomen's Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company 4Health News:Doctors' Guide to Cancer Drugs May Need Revising 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 3Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 4Health News:Tyler Perry Donates $110K to Covenant House Keeping Atlanta Teens off the Street 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: